CORT
Corcept Therapeutics Incorporated
CORT has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CORT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
CORT's revenue, profitability, cash flow and balance sheet are all currently strong.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CORT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $73.71 | — |
| Cheap | 22x | $27.59 | -63% |
| Fair | 29x | $36.55 | -50% |
| Current | 58x | $73.71 | — |
| Expensive | 59x | $75.21 | +2% |
Historical ranges are pointers, not guarantees.
CORT's PE is in its expensive range at 58x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over CORT in the historical PE scenario, which offers more potential upside but is not a forecast.
CORT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
CORT has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CORT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.42 | +248% |
| Q3 2026 | $1.27 | +46% |
| Q2 2026 | $0.42 | -63% |
| Q1 2026 | $0.35 | -70% |
| Q4 2025 | $0.82 | -33% |
| Q3 2025 | $0.87 | -30% |
| Q2 2025 | $1.12 | 0% |
| Q1 2025 | $1.15 | +9.5% |
| Q4 2024 | $1.23 | +31% |
CORT earned $1.27 per share over the past year, up 46% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CORT on earnings, with more consistent year-over-year improvement.
CORT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $340.5M | +64% |
| Q2 2026 | $256.1M | +32% |
| Q1 2026 | $164.9M | +4.9% |
| Q4 2025 | $202.1M | +11% |
| Q3 2025 | $207.6M | +14% |
| Q2 2025 | $194.4M | +19% |
| Q1 2025 | $157.2M | +7.1% |
| Q4 2024 | $181.9M | +34% |
CORT has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +29 points |
| Q2 2026 | 16% | +2.4 points |
| Q1 2026 | -30% | -32 points |
| Q4 2025 | 2.2% | -12 points |
| Q3 2025 | 4.9% | -21 points |
| Q2 2025 | 14% | -8 points |
| Q1 2025 | 2.2% | -18 points |
| Q4 2024 | 14% | -9.5 points |
CORT's operating margin was 34% last quarter, up 29 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CORT on profitability, with a higher operating margin.
CORT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $142.2M | +161% |
| Q2 2026 | $31M | -29% |
| Q1 2026 | -$17M | -438% |
| Q4 2025 | $38.4M | -35% |
| Q3 2025 | $54.5M | -25% |
| Q1 2025 | $5M | -79% |
| Q4 2024 | $59.2M | +905% |
| Q3 2024 | $72.2M | +37% |
CORT generated $195M in free cash flow over the past year, up 20% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CORT on cash flow, with more consistent year-over-year improvement.
CORT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +4.8M shares |
| 1 year | +3.1% | +3.8M shares |
| 3 years | +11% | +12.1M shares |
| 5 years | -1.5% | -1.9M shares |
| Available history | +0.5% | +635K shares |
CORT has 123M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.7M |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $42.5M |
| Q2 2025 | $103M |
| Q1 2025 | $27.4M |
| Q4 2024 | — |
CORT has spent almost nothing on buybacks in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CORT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CORT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -13.2x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
CORT has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CORT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 3.4 | Oversold |
CORT's weekly RSI is 39 (neutral) and its Stochastic is 3 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CORT PE vs Healthcare Sector
| Metric | CORT | Sector median | Relative |
|---|---|---|---|
| PE | 58x | 26x | 125% above |
| PE % | 82 | 29 | 53 pts above |
CORT is trading at 58x earnings, a 125% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over CORT on valuation relative to its sector.
CORT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.1 | 24% below |
| 20 week MA | $102.8 | 28% below |
| 50 week MA | $73.4 | 0.4% above |
| 100 week MA | $71.2 | 3.6% above |
| 200 week MA | $50.5 | 46% above |
CORT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CORT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.3 | $27.2 | +121% |
| 2021 | $27.2 | $19.9 | -27% |
| 2022 | $19.9 | $20.7 | +4% |
| 2023 | $20.7 | $32.5 | +57% |
| 2024 | $32.5 | $52.5 | +62% |
| 2025 | $52.5 | $82.7 | +58% |
| 2026 YTD | $82.7 | $73.7 | -11% |
CORT has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.